Jeligo

Linagliptin, the active ingredient in Jeligo, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus when diet, exercise, and other therapies are insufficient.

GNH USA supplies Jeligo as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers. Its distribution network ensures timely delivery and regulatory compliance across multiple regions.

Linagliptin is used to manage hyperglycemia in the type 2 diabetes mellitus pathway.

- Type 2 diabetes mellitus: improves glycemic control as monotherapy or in combination with other antidiabetic agents. - Adjunct to diet and exercise: helps patients achieve target HbA1c when lifestyle measures alone are insufficient. - Combination therapy: used alongside metformin, sulfonylureas, or insulin to enhance overall glucose management.

Linagliptin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient cranial pain. - Dizziness: sensation of light-headedness. - Gastrointestinal discomfort: nausea, abdominal pain or diarrhea.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe hypersensitivity reactions: skin rash, angioedema, or anaphylaxis. - Hepatic injury: marked elevation of liver enzymes or jaundice.

Before initiating therapy, clinicians should consider several precautionary measures.

- Renal function: assess baseline and monitor periodically, especially in patients with impairment. - Pancreatitis risk: discontinue if signs of acute pancreatitis appear. - Hepatic monitoring: evaluate liver enzymes before initiation and during therapy. - Cardiovascular status: use cautiously in patients with a history of heart failure. - Hypersensitivity: avoid in individuals with known allergy to linagliptin or DPP-4 inhibitors. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Linagliptin can interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase linagliptin exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce linagliptin effectiveness. - Concurrent use with insulin or sulfonylureas: heightened risk of hypoglycemia.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate blood pressure changes; monitor electrolytes. - Antihypertensive agents: additive blood pressure lowering effect; observe hemodynamic status.